Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”
Ana da Silva Filipe(MRC University of Glasgow Centre for Virus Research), Emma C. Thomson(MRC University of Glasgow Centre for Virus Research), Martin Wiselka(University Hospitals of Leicester NHS Trust), Mark Aldersley(St James's University Hospital), Vattipally B. Sreenu(MRC University of Glasgow Centre for Virus Research), Joseph Hughes(MRC University of Glasgow Centre for Virus Research), John McLauchlan(MRC University of Glasgow Centre for Virus Research), Paul Richardson(University of Liverpool), Graham R. Foster(Queen Mary University of London), Kosh Agarwal(King's College - North Carolina), William L. Irving(University of Nottingham), William Rosenberg(University of Southampton), Elihú Aranday-Cortés(MRC University of Glasgow Centre for Virus Research), Douglas MacDonald(Royal Free London NHS Foundation Trust), Andrew Ustianowski(North Manchester General Hospital)
Cited by 2
Related Papers
HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Serum markers detect the presence of liver fibrosis: A cohort study
|Gastroenterology|2004|1.1k
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
|Cell|2020|1.1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877